Proactive Investors - Run By Investors For Investors

CymaBay stock bombs after seladelpar disappoints in a study for its liver treatment

The California company’s NASH ambitions hit a wall as reductions in liver fat were minimal and not significant compared to placebo
A generic representation of a liver
CymaBay Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases

CymaBay Therapeutics Inc (NASDAQ:CBAY) tumbled in pre-market trade Tuesday after the company’s lead drug, seladelpar, posted disappointing results in a mid-stage clinical trial linked to nonalcoholic steatohepatitis (NASH).

NASH is liver inflammation and damage caused by a buildup of fat in the liver. Patients with this disease are often told they have a "fatty liver."

In the Phase 2 study, three oral doses of seladelpar, all performed worse than a harmless placebo, based on a non-invasive imaging test that measures decreases in liver fat.

Investors sent shares in the Newark, California-based company down nearly 40.4% to $6.60 in pre-market trade.

READ: Shares of CymaBay Therapeutics gain after study signals Seladelpar treatment shows 'efficacy'

The study had enrolled 181 patients with moderate stage of NASH and treated them for 12 weeks.

Reductions in liver fat were minimal and “not significant” compared to a placebo, said the company in a statement.

“While the reductions in liver fat were minimal, we remain encouraged by the significant improvements in biochemical markers of liver injury that we observed at week 12,” said Dr Pol Boudes, chief medical officer at CymaBay Therapeutics.

Boudes said the 52-week liver biopsy data will allow the company to understand whether the improvement in liver injury markers will translate into histological, or microscopic improvement.

“The observed improvement in markers of liver injury are consistent with the observed effects of seladelpar in PBC and further support the potential for seladelpar to improve liver health,” said Boudes.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

View full CBAY profile View Profile

Related Articles

April 05 2019
Chief executive Peter Butterfield said the company has started 2019 well-positioned for growth after a strong performance in 2018.
Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
human kidneys
May 06 2019
The Danish company is seeking FDA approval of the test for use in both adults and children

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use